Replies to post #62830 on $heff's $tation of $tocks & $olid DD

[StimulatedCell]

I don't really believe APF530 will be able to claim a lion's share of CINV market right away. While the one slide states Zofran is not effective for CINV I feel pretty certain it is used off-label for this problem and probably is more effective than the slide suggests. The QT interval issue is not that big of a problem as APPA want you to believe. In summary, Zofran, not Anzemet, is the Goliath that will have to be dealt with.